Lazarus Benjamin, Kotwal Sradha, Gallagher Martin, Higgins Kathryn, Coggan Sarah, Gray Nicholas A, Talaulikar Girish, Polkinghorne Kevan R
The George Institute for Global Health, University of New South Wales, Sydney Australia.
Department of Medicine, Monash University, Clayton, Victoria, Australia.
Kidney Med. 2025 Jun 2;7(8):101042. doi: 10.1016/j.xkme.2025.101042. eCollection 2025 Aug.
RATIONALE & OBJECTIVE: It is unknown whether administration of prophylactic systemic antibiotics immediately before tunneled catheter insertion can prevent early hemodialysis catheter-related bloodstream infections (HDCRBSI). We aimed to estimate the effect of systemic prophylactic antibiotics on early HDCRBSI.
An observational secondary analysis using data from the nationwide REDUcing the burden of dialysis Catheter ComplicaTIOns: a National approach trial.
SETTING & PARTICIPANTS: Adults with an incident hemodialysis catheter inserted in one of 37 Australian nephrology services from December 2016 to March 2020.
Service-wide policy of systemic prophylactic antibiotic use before tunneled catheter insertion determined by response to a prestudy survey.
HDCRBSI within 14 days of catheter insertion, independently adjudicated by a blinded panel using modified Infectious Diseases Society of America criteria.
Multilevel logistic regression to compare outcomes among antibiotic-using and nonusing services.
Six services (900 patients) used prophylactic antibiotics, and 23 services (3,702 patients) did not. Among the 1,196 tunneled catheters that were inserted in antibiotic-using services, 4 (0.3%) had HDCRBSI and another 10 (0.8%) had infectious removal within 14 days of insertion. Among the 5,027 tunneled catheters inserted in nonantibiotic-using services, 40 (0.8%) had HDCRBSI and another 41 (0.8%) had infectious removal within 14 days. The odds of early HDCRBSI were not significantly different between antibiotic-using and nonusing services in the unadjusted (OR, 0.42; 95% CI, 0.15-1.17) or adjusted models (adjusted OR, 0.59; 95% CI, 0.20-1.80).
Prophylactic systemic antibiotic use was determined at a service level and was not randomly assigned to individuals.
In Australia, less than 1% of tunneled catheters had confirmed HDCRBSI within 14 days of insertion. Routine administration of prophylactic antibiotics before insertion of tunneled cuffed catheters was not associated with a reduced occurrence of early HDCRBSI within 14 days.
在置入带隧道的导管之前立即给予预防性全身抗生素治疗是否能够预防早期血液透析导管相关血流感染(HDCRBSI)尚不清楚。我们旨在评估全身预防性抗生素对早期HDCRBSI的影响。
一项观察性二次分析,使用来自全国性的“减轻透析导管并发症负担:一项全国性方法试验”的数据。
2016年12月至2020年3月期间,在澳大利亚37个肾脏病服务机构之一置入首次使用的血液透析导管的成年人。
根据对一项预研究调查的回复确定的在置入带隧道的导管之前使用全身预防性抗生素的机构范围政策。
导管插入后14天内发生的HDCRBSI,由一个盲法小组根据美国感染病学会修改后的标准进行独立判定。
采用多水平逻辑回归比较使用抗生素和未使用抗生素的机构之间的结局。
6个机构(900例患者)使用了预防性抗生素,23个机构(3702例患者)未使用。在使用抗生素的机构中插入的1196根带隧道的导管中,4根(0.3%)发生了HDCRBSI,另有10根(0.8%)在插入后14天内因感染而拔除。在未使用抗生素的机构中插入的5027根带隧道的导管中,40根(0.8%)发生了HDCRBSI,另有41根(0.8%)在14天内因感染而拔除。在未调整的模型(比值比[OR],0.42;95%置信区间[CI],0.15-1.17)或调整后的模型(调整后OR,0.59;95%CI,0.20-1.80)中,使用抗生素和未使用抗生素的机构之间早期HDCRBSI的发生几率无显著差异。
预防性全身抗生素的使用是在机构层面确定的,未随机分配给个体。
在澳大利亚,不到1%的带隧道的导管在插入后14天内确诊发生HDCRBSI。在插入带隧道的带袖套导管之前常规给予预防性抗生素与14天内早期HDCRBSI发生率降低无关。